Abstract
Abstract: :
Purpose:To investigate the effect of Infliximab on macula edema in patients suffering from different types of uveitis. Material and Methods:Five female patients (seven eyes) with macula edema were enrolled in the study due to a lack of efficacy of other therapeutics. Patients 1 and 2 were suffering from HLA–B27 associated chronic uveitis (two eyes), patient 3 (two eyes) from an idiopathic intermediate uveitis (two eyes), patient 4 from disseminated chronic chorioretinits (two eyes), and patient 5 was suffering from Birdshot disease (one eye). Patient 1 and 2 had an acute edema , the other patients were all suffering from chronic edema (> three months). Flouresein angiography or OCT were performed in all eyes. All patients were treated at a dose of 5mg/kg/BW at week 0, 2, 6, and 8. Results:All eyes but one (patient 5 did not show any effect) responded with a decrease of the macula edema and an increase of vision by at least 2 lines in the EDTS chart already after the second infusion. Conclusions:Infliximab appears to be a potent medication to treat people with uveitis associated macula edema, depending on their underlying disease.
Keywords: uveitis-clinical/animal model • cytokines/chemokines